Podcasts about Sequencing

A bad strategy can trick you into giving up on the right dream. The problem isn't what you want… it's how you're trying to get it.  Turns out, there's a totally different way of planning your life that's going to get you going to get you further faster. My guest Courtney De Ronde dropped a line in this conversation that stopped me cold: “We give up on our vision instead of shifting our strategy.”  You may not have the wrong dream. You may just be taking the wrong road to get there. In this episode, we're breaking down why smart, motivated people get stuck and how to build a life plan that actually moves you forward. You'll learn: Why trying harder may actually keep you stuck The difference between your vision and your strategy How to turn a big dream into something you can actually do this week Whether you're a visionary or a doer, and how each gets derailed How to know when it's time to change course instead of giving up Why the thing you keep calling a “discipline problem” might actually be a support problem Courtney's framework moves from a long-term vision to a realistic annual milestone and finally into the days, weeks, and quarters where progress actually happens.  Before you decide the dream isn't going to happen, make sure you're not just stuck on the wrong road. Take the free “What's Holding You Back?” quiz to figure out where you're getting stuck. And if you're ready for support creating a different path forward, schedule a free consultation with a coach at Growing Self. Xoxo, Dr. Lisa Marie Bobby Growing Self Special thanks to this month's sponsors of the podcast: Shopify —  Every self-made person started somewhere. Yours starts free at shopify.com/lhs Quince — Quality products you'll actually use that feel like luxury without the price tag. Get free shipping and 365-day returns at ⁠quince.com/lhs⁠ Sequencing.com — Discover what your DNA can reveal about your health with clinical-grade whole genome sequencing that reads 100% of your DNA. Get 10% off with promo code LHS at Sequencing.com

In this episode, we spoke with Arndt Vogel, MD, a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre in Canada.In our exclusive interview, Dr Vogel highlighted the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma, explaining that on-target resistance mutations and the differing binding properties of agents like pemigatinib (Pemazyre), futibatinib (Lytgobi), and the more selective tinengotinib (TT-00420) support using these drugs in sequence, although he emphasized that treatment decisions remain biomarker-informed rather than biomarker-guided. He also stressed the importance of early, RNA-based next-generation sequencing, the emerging role of circulating tumor DNA in capturing polyclonal resistance, and his anticipation of forthcoming phase 3 tinengotinib data.

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program:https://bit.ly/3TZSmufGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Reach Out: Please include your email and I will get back to you. Thanks!GENESIS, EXODUS, LEVITICUS, NUMBERS, DEUTERONOMY: JESUS BOOKS (Book on Amazon)emersonk78@me.comExcel Still More Journal - AmazonNew GENESIS Daily Bible Devotional!Daily Bible Devotional Series - AmazonSponsor: Jon Cunningham, Cunningham FinancialEmail: jon@cunninghamfinancialgroup.comPhone: 205-913-1720Sponsor: Tyler Cain, Senior Loan Officer Email: Tcain@embracehomeloans.comPhone: 813-380-8487Simon Sinek's Start With Why challenges us to begin with the deeper purpose behind what we do. That principle has powerful applications for faith and relationships. In the Christian life, the sequence matters: Grace, Faith, Life. We begin with what God has done for us. His grace produces faith, and genuine faith shapes the way we live. Too often, we start with behavior and work backward. But when we understand the “why,” everything changes. In this episode, we explore how starting with grace can deepen our faith, strengthen our relationships, and produce a life that flows naturally from gratitude, purpose, and love.

In this episode, medical oncologist Dr. Chandrikha Chandrasekharan from MD Anderson Cancer Center breaks down how treatment decisions are made and sequenced for patients with neuroendocrine neoplasms (NENs). The conversation explores what “benign” and “indolent” really mean, how treatment goals are defined, and how clinicians balance effectiveness, side effects, and long-term strategy. Dr. Chandrasekharan discusses sequencing therapies without burning bridges, when treatments can be reused, how prior response informs future decisions, and when to consider clinical trials. The episode emphasizes shared decision-making, aligning treatment plans with patient values, and navigating care with clarity rather than fear.TOP TEN QUESTIONS1. Is Neuroendocrine Cancer ever “benign”? What does “benign” actually mean in the context of neuroendocrine tumors?When might a tumor be considered benign, and when is it clearly malignant?Can neuroendocrine cancer be “cured”?How should patients understand tumor behavior if they've been told theirs is slow-growing or “indolent”?2. What is the real goal of treatment?Can I go into “remission”? Is it to make all the tumors disappear?Many patients describe feeling like they have a ticking time bomb inside them. Can you speak to that fear and how treatment goals are set?3. Which treatment works “the best”? How do we even define “best” when it comes to neuroendocrine cancer?4. Which treatments tend to have the fewest side effects? How should patients think about balancing effectiveness with quality of life?5. How can someone know which treatment is right for their type of neuroendocrine cancer and their current situation? What factors matter most?6. Is there a “best way” to sequence treatments?How do patients and clinicians prioritize options in a way that doesn't “burn bridges” for the future?How do age, gender, race, and ethnicity influence treatment decisions, if at all?7. If a treatment worked well for me before, is it possible to use it again?If a treatment does not work well, what does that mean? Does it predict how I might respond to another therapy? Does it imply anything about my overall prognosis?8. What are the “big guns,” and when should they be used?Is there such a thing as “wasting” a treatment?9. When should someone consider clinical trials?Should clinical trials be considered only after standard treatments, or earlier?10. What advice do you have for people who receive differing opinions from their provider(s)?Bonus: What advice do you have for patients in communicating their values and preferences with their providers?ABOUT THE SPEAKERDr. Chandrikha Chandrasekharan is a Clinical Associate Professor at MD Anderson Cancer Center, where she has focused on neuroendocrine tumors and pancreatic cancer since January 2025. She is a dual board-certified physician in Medical Oncology and Palliative Medicine.Dr. Chandrasekharan earned her medical degree from Kilpauk Medical College in India. She completed her internal medicine residency at the University of Florida College of Medicine in Jacksonville, followed by a fellowship in Palliative Medicine at Mayo Clinic, Rochester. She then pursued a fellowship in Medical Oncology at LSU Shreveport, and further specialized in gastrointestinal malignancies with an additional year of training at Mayo Clinic, where she developed a strong interest in neuroendocrine tumors.Prior to joining MD Anderson, Dr. Chandrasekharan served for eight years as a Clinical Associate Professor at the University of Iowa. There, she co-led the gastrointestinal oncology program and treated a broad range of GI malignancies. From 2021 to 2022, she was Co-Director of the Clinical Core for the Neuroendocrine Tumor SPORE.She is an active member of the North American Neuroendocrine Tumor Society (NANETS), currently serving as Co-Chair of the NANETS Annual Symposium Planning Committee, and previously chaired the Regional Medical Education Committee. In addition to her clinical and academic work, Dr. Chandrasekharan is engaged in clinical trials and research focused on healthcare outcomes, health equity, and global oncology care.Visit https://www.ncf.net/podcast/55 for more resources. For more information, visit NCF.net. 

You've got the framework figured out. You could build ten different offers tomorrow if someone asked you to. That's exactly the problem.This is Part 2 of the solar system series, and if you haven't heard Part 1 yet, go back and listen first. Adam and Jess already covered the Sun, your core gravitational pull, the tension you solve over and over. Today they're building the next layer out: the Planet.A planet is your singular offer, payoff, or outcome built around that Sun. If your Sun is uncertainty, your planet might be a specific group coaching container that solves one defined outcome. Not three offers. Not a menu. One. Adam openly admits he wanted to build a dozen planets when they first mapped this model together. Jess shut that down immediately, and this episode is why.The instinct to build everything at once is a visionary trait, not a strategy. Jess makes the case that people should be able to name your planet the way they name Earth or Mars, instantly, without effort. When your offer is that clear, your network stops needing you to explain yourself and starts being able to refer you. That's the entire point of "I know a guy." Nobody refers a menu.What you'll learn:Why one clearly defined offer builds more referral traffic than a full suite of servicesThe difference between your Sun (the problem you solve) and your Planet (the specific offer built around it)Why the planet includes naming the container, the "how," not just the outcomeHow going one-on-one first, before building out a full offer suite, sharpens your language fasterWhy a single clear offer lets you price the payoff instead of pricing yourselfHow having one planet actually crushes imposter syndrome instead of feeding itWhy doing things in sequence, not all at once, makes you faster, not slowerThe big idea: A menu of offers feels like more value. It's actually the reason people can't refer you, price you accurately, or trust you. One planet, clearly named, is what makes an offer easy to invite people into instead of something you have to sell.Notable quote: "Great, but which one are we colonizing first?" — Jess Webber, on the twelve things Adam wanted to build when they metResources mentioned:Walt Disney's original mind map, referenced by Adam as an example of one Sun (Walt Disney Studios) spawning multiple planets over time: framerusercontent.com/images/eNS3np8QbwJRoO7t8fBSR7Yts.jpgEp. 192, "I Know a Guy, Pt. 1: Find Your Coaching Gravity" (referenced throughout)ILC community: ilovecoachingco.comInstagram: @ilovecoachingco / @adamrroach / @thejesswebberYouTube: youtube.com/@ilovecoachingcoTimestamps: [00:00] Intro: back in the solar system for episode 2 [00:30] Quick recap: the Sun from Episode 1 [01:18] Today's topic: the Planet, and why it's one, not twelve [02:22] Defining the planet: your singular offer around the Sun [03:10] Why "one" gets the emphasis (Rocket Fuel results: 50/50 Visionary-Integrator) [04:36] The nerd test: people should be able to name your planet like Earth or Mars [05:43] How clarity turns your network into mouthpieces for you [05:52] Adam's recruiting story: "150 people in a year" as his one planet [06:56] Why they teach one-on-ones first, in reverse of Adam's own path [07:12] The planet includes naming the container, not just the payoff [07:29] No menu of offers, no menu of outcomes [08:10] "Which one are we colonizing first?" [09:20] Sequencing beats doing it all at once [09:46] Preview: next episode covers the Moons [10:58] Why one clear offer builds more trust than a menu, and lets you price the payoff [11:19] Why they're not talking about sales yet: confused people do nothing [12:16] Confidence and imposter syndrome: the burden of handing someone a Sun [14:11] Walt Disney's mind map: Walt Disney Studios as the original Sun [15:04] Slowing down to speed up [15:25] Why talented coaches still fail: it's clarity, not skill [16:41] Wrap and tease: next time, the MoonsJoin the community:Ready to stop juggling a dozen ideas and build the one offer people can actually refer you for? The Sellable Offer Challenge walks you through it: ilovecoachingco.com/challenge

Not every renovation needs to happen all at once. In this episode, Craig Stadelmann, Project Executive at S+H Construction, joins Sarah and Bruce to discuss how thoughtful planning and strategic sequencing can help homeowners balance budgets, construction logistics and the realities of living through a renovation. The conversation explores how to prioritize projects, coordinate infrastructure and related spaces, minimize disruption and avoid unnecessary rework. Craig also shares why a collaborative master plan, developed with the homeowner, architect, designer and builder, can make phasing more cost-effective while allowing for better-informed decisions and a more manageable renovation experience.Builder's Notebook is recorded and produced by JDCommunications, Inc.Theme music by Sean Ryan Peters

What if one of the biggest secrets to long-term Weight Mastery isn't making better decisions all day long—but making fewer decisions in the first place? Over the years, I've realized that so much of what keeps me healthy and maintaining my weight isn't willpower. It's sequencing. One thing cues the next, the next thing cues the next, and eventually those healthy patterns become so familiar that I barely have to think about them. In this episode, I'm taking you inside my morning routine—and we'll look at the science of habit and automaticity, how old Weight Struggle sequences get wired in without us realizing it, and how you can begin creating simple new sequences that support your health, your Inner Coach, and your long-term Weight Mastery. Come on in!   ​Join Our Live Fall 2026 Shift Weight Mastery Process​ ​ ​In This Episode, You'll Also Learn… Why 43% of what you do every day is running on autopilot—and why "Why am I doing this again?" is usually a well-practiced path, not a character flaw Why the "21 days to a habit" rule isn't real, what the research actually found, and why missing a day doesn't undo a thing How to pack your anchors instead of your whole routine when you travel—and why "everything falls apart on vacation" is about missing cues, not missing discipline   Links Mentioned in the Episode: Join my FREE Masterclass:  "How to Stop the "Start Over Tomorrow" Weight Struggle Cycle and Begin Releasing Weight for Good." Sign up for the FREE HYPNOSIS DOWNLOAD:  Shift Out of Sugar Cravings My book,  From Fat to Thin Thinking: Unlock Your Mind for Permanent Weight Loss (Includes a 30-day hypnosis process.) What would you love to hear about on the podcast?  Click here and let me know Subscribe to the email list so that you never miss an episode! Get more thin thinking tools and strategies

In today's episode, we spoke with Raji Shameem, MD, and Shubham Pant, MD, MBBS. Dr Shameem is a clinical assistant professor of medicine at the Orlando College of Osteopathic Medicine, an assistant professor of Medicine at the University of Central Florida, and a physician at Orlando Health. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology and the Department of Investigational Cancer Therapeutics, as well as the director of Clinical Research at The Sheikh Zayed Center For Pancreatic Cancer Research at The University of Texas MD Anderson Cancer Center in Houston.In our exclusive interview, Drs Shameem and Pant discussed the rapidly evolving pancreatic cancer treatment paradigm, going in-depth on topics like the role of liposomal irinotecan (Onivyde), the FDA approval of daraxonrasib (Rasonque) for patients with metastatic disease, and novel treatments that are in development. The 2 experts also covered which directions they see the pancreatic cancer field moving towards in the future.

Bill Kanasky, Jr., Ph.D. talks about a deposition topic that doesn't get enough attention: the question sequencing in a Reptile deposition. Bill describes how the setup questions that precede the transition point to Reptile/Edge questions lull the witness's brain into a state of safety which prevents them from recognizing the subtle transition to the dangerous Reptile/Edge questions. The witness's brain becomes comfortable with the basic, simple, fact-based questions being asked and doesn't realize when the questions change from safe to risky. Most attorneys prepare their witnesses for the "standard" Reptile safety questions. What's missing is that these Reptile questions about safety are actually the secondary threat - the setup questions are the primary threat and this is what witnesses need to understand and be prepared for. Detecting the transition to the risky Reptile questions is difficult, however, with neurocognitive training, can be done. Watch the video of this episode: https://youtu.be/vNjF1kqzS8U

It's often said that a case is won — or lost — during direct examination. Former prosecutor Steve Wood explores why direct really comes down to effective storytelling, ways to organize your direct examination, and how to ask questions that not only elicit good answers but also help the trier of fact follow the narrative. He also touches on how to cut through the inevitable fog of boredom by introducing purposeful change into the courtroom environment. Topics2:44 Goals of direct examination3:37 Why storytelling matters in direct5:16 Storytelling elements14:01 Breaking through the fog of boredom23:11 Sequencing your questions26:05 Using your voice28:45 Organizing your direct31:57 Accrediting the witness36:18 Telling the story41:17 Honesty and bad facts44:24 Questioning the witness47:02 Phrasing your questions59:39 Word choice1:02:00 Witness focus1:05:51 Plain English1:09:46 Tenacity1:12:37 Runaway witnesses1:16:36 Signoff questionQuote“One of the things that happens in every trial is that there is a contest for credibility between the advocates. I don't — and can't — lose that contest. And if a jury hears something bad from the other side first, they might be thinking I was trying to hide something from them.” Steve WoodResourcesSteve Wood (LinkedIn)Building Trial Skills: New Jersey (program)Top 10 Tips that Make a Difference (podcast episode)“Don't Be Boring”: Creating Your Commanding Courtroom Presence (podcast episode)Cross-Examination: Do No Harm (free webcast)

MTCT #207: Sequencing Instruments and Songwriting with Tony Hartman by Carrie Nicholas and Tanya LeJeune

After decades of steady paychecks, retirement asks a new question: where does the money come from now, and in what order? In this episode of Purposeful Planning, Troy Fore, CFP®, walks through retirement income sequencing, or the order in which you draw from Social Security, pensions, savings, and investment accounts. It is a decision that shapes your taxes, your exposure to market downturns, and how long your money lasts, and getting it right can bring real peace of mind to your retirement income. Sources: • Building Your Retirement Paycheck: Income Sequencing Strategies for the First Years of Retirement (Aspen Wealth Management): https://www.aspenwealthmgmt.com/resource-center/retirement/retirement-income-sequencing-strategy • Creating a Flexible Spending Plan for Your First 10 Years of Retirement (Aspen Wealth Management): https://www.aspenwealthmgmt.com/resource-center/retirement/retirement-spending-plan-first-decade • Longevity Risk and Financial Security: Planning for a Longer Retirement (Aspen Wealth Management): https://www.aspenwealthmgmt.com/resource-center/retirement/longevity-risk-financial-security/ • You've Done a Good Job Saving It: Do You Know the Best Way to Spend It? (Aspen Wealth Management): https://www.aspenwealthmgmt.com/resource-center/tax/retirement-withdrawal-strategies/ • Contact Aspen Wealth Management: https://www.aspenwealthmgmt.com/contact-us-fee-only-advisors-fort-worth The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. This information has been derived from sources believed to be accurate and is intended merely for educational purposes, not as advice. Hosted on Acast. See acast.com/privacy for more information.

Highlights from the PER® CME activity "The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Seth A. Wander, MD, PhD, Reshma L. Mahtani, DO, and Shanu Modi, MD, review pivotal data regarding the use of antibody-drug conjugates in the treatment of metastatic triple-negative breast cancer, and discuss how they apply these data in the management of their patients.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/the-adc-revolution-in-metastatic-breast-cancer-redefining-treatment-selection-and-sequencing-kpppThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Today we tackle one of the foundational TCG concepts of "Sequencing": how it applies to Flesh and Blood, how we can use it for better deckbuilding, and various tips, tricks, and fringe cases that can help you use sequencing to win more games.Discord Link: https://discord.gg/HR4pJpcdZ8 Patreon Link: https://patreon.com/PitchItToMe?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_fan&utm_content=join_linkYou can follow us at the following socials:Bluesky: https://bsky.app/profile/pitchittomepod.bsky.socialInstagram: https://www.instagram.com/pitchittomepodcastYoutube: https://www.youtube.com/@PitchItToMePodcastTimestamps:00:00 Introduction00:37 Turn Zero08:26 Sequencing for Value23:46 Categorization and Hand Textures43:05 The Human Element59:22 Arsenal Zone1:11:45 OutroCredits:Host #2 -- Fuzzy DelpHost #2 -- Joel RecinosHost #2 -- Clark MooreExecutive Producer -- Talon StradleyMusic -- Dillon HulseLogo -- Han ViMix -- Christopher MooreAudio Editor -- Joel RecinosVideo Editor -- Clark MooreThank you to Legend Story Studios for allowing the use of their card art through their Content Creator policies and for making the game of Flesh and Blood.#fleshandbloodtcg #tradingcards #gamedesign #podcast #legendstorystudios #fabtcg #pitm #pitchittome #sequencing #competitive

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitisConsiderations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistancePresenters:BJ Rimel, MDDivision Chief, Gynecologic OncologyProfessor, Department of OB/GYNUniversity of WashingtonClinical Director of Gynecologic OncologyFred Hutchinson Cancer CenterSeattle, WashingtonElizabeth Lee, MDDivision of Gynecologic OncologyCenter for Cancer Therapeutic InnovationDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsLink to full program: https://bit.ly/3SqCAZ6Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our Changing World takes a deep dive into controversial plans by US company Colossal Biosciences, backed by filmmaker Peter Jackson, to de-extinct the Moa. In part one of a two-part series, Sharon Brettkelly looks at whether it CAN be done.Sign up to the Our Changing World monthly newsletter for episode backstories, science analysis and more.LEARN MORE:Colossal Biosciences claims they have de-extincted the dire wolf, from CNN.More detail on Colossal Biosciences' artificial egg.Listen to Kathryn Ryan speaking with ‘Mr Moa' - paleozoologist Trevor Worthy about his long career.Auckland Museum research associate Daniel Thomas talks to Tuwhenuaroa Natanahira about the discovery of million year old moa footprints.GUESTS:Dr Andrew Pask, Chief Biology Officer, Colossal BiosciencesAssociate Professor Nic Rawlence, Director of Otago Palaeogenetics Laboratory, University of Otago.IN THIS EPISODE:(00:00) Could we bring the moa back?(02:30) Sequencing the moa genome(06:00) DNA data(08:00) The artificial egg breakthrough(10:20) How a "moa" would actually be created(12:30) Critics challenge the science(17:20) The conservation implications(22:00) Māori consultation questions(23:51) Will we ever see moa roaming again?(26:08) Coming up in Part 2Go to this episode on rnz.co.nz for more details

In this episode of The Dairy Nutrition Blackbelt Podcast, Dr. Clarissa Strieder-Barboza, Assistant Professor of Veterinary Sciences at Texas Tech University, explains how adipose tissue influences metabolic adaptation, inflammation, ketosis risk, and transition cow performance. She discusses emerging research on adipose tissue remodeling, cellular specialization, and biomarkers that may improve health and productivity during early lactation. Listen now on all major platforms!"Adipose tissue from cows with subclinical ketosis can be metabolically different before clinical signs appear."Meet the guest: Dr. Clarissa Strieder-Barboza is an Assistant Professor of Veterinary Sciences at Texas Tech University. Her research focuses on adipose tissue biology, immunometabolism, metabolic disease, and transition cow physiology. She investigates how adipose tissue remodeling, inflammation, and metabolic adaptation affect dairy cattle health and productivity. Hear more from Dr. Strieder-Barboza on The Dairy Nutrition Blackbelt Podcast, available on all major platforms.Liked this one? Don't stop now — Here's what we think you'll love!What will you learn: (00:00) Highlight(02:12) Introduction(02:50) Adipose importance(05:12) Ketosis regulation(08:17) Sequencing tools(10:53) Cell subtypes(11:46) Metabolic resilience(15:12) Closing thoughtsThe Dairy Nutrition Blackbelt Podcast is trusted and supported by the innovative companies:* Barentz* Priority IAC* Adisseo* Vetagro* Kemin* Fortiva- Esmilco Inc.- Virtus Nutrition- DietForge

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics: ·      Introduction (0:00) ·      Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29) ·      Recent Advances in Up-Front Treatment for Metastatic PAD (15:47) ·      Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58) ·      Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20) ·      Utility of Tumor Treating Fields in PAD Management (1:13:58) CME information and select publications

The "podcast no one asked for" is back as hosts Silvia Radenkovic and James Nurse preview the 2026 SSIEM Annual Meeting, and they are joined by meeting chair Risto Lapatto to discuss what goes in to arranging an international IMD conference, the sessions he doesn't want to miss and why you have to try a sauna. We want to hear from you across the week so if you've got a poster in Helsinki please get in touch and we will find you!!

New class every Tuesday. 350+ full classes in the Unlimited Archive at JustGreatYoga.com

In this episode of The Private Equity Podcast, Alex Rawlings is joined for a second time by Brian Gustason, Fractional Operating Partner at BG Operating Advisors.Brian explains why many lower-middle-market businesses struggle to scale after receiving institutional investment and how private equity firms can professionalise their go-to-market strategy.The conversation explores founder dependency, underdeveloped sales and marketing capabilities, and why firms must assess the maturity of the entire revenue engine before attempting to accelerate growth.Brian also outlines the importance of route-to-market analysis, including reach, fit and yield, and explains why growth should be treated as an interconnected system covering marketing, sales and customer success.The episode also examines go-to-market integration within roll-up strategies, the importance of execution fit during due diligence and how operating partners can help portfolio companies sequence growth initiatives more effectively.Key HighlightsWhy founder-led businesses often struggle to scaleThe risks of founder dependency in salesWhat Brian means by “phase zero” capabilitiesWhy firms may need to go backwards before scaling forwardsHow to professionalise a go-to-market strategyThe importance of route-to-market analysisUnderstanding reach, fit and yieldWhy lower-middle-market businesses hit growth ceilingsThe challenges of integrating founder-led businesses in a roll-upWhy go-to-market integration should be pre-wiredThe importance of execution fit during due diligenceWhy growth stalls are not always sales problemsCustomer success versus customer supportHow existing customers can drive expansion revenueSeparating revenue results from the revenue engineHow operating partners can support commercial transformationWhy growth initiatives must be sequenced correctlyTimestamps00:00 – Introduction to Brian Gustason and BG Operating Advisors01:01 – Common growth challenges in the lower-middle market01:31 – Founder dependency and underdeveloped commercial capabilities02:29 – Identifying phase zero go-to-market capabilities03:56 – Defining a professionalised go-to-market strategy04:23 – The role of go-to-market strategy in private equity05:17 – Why route-to-market analysis is often overlooked05:47 – Understanding reach, fit and yield07:14 – Why founder-led businesses often lack scalable processes08:38 – Growth ceilings and limited execution runway10:05 – Go-to-market challenges in roll-up strategies11:34 – Pre-wiring go-to-market integration13:01 – How deal origination affects integration13:58 – Execution fit and time to integration value15:51 – Diagnosing the real causes of stalled growth16:40 – Treating go-to-market as a connected system17:08 – The role of customer success in recurring revenue18:33 – Unlocking growth from existing customers19:53 – Assessing whether the revenue engine can scale20:22 – Separating revenue performance from revenue capability21:20 – Evaluating go-to-market maturity22:42 – Where to play, who to target and how to engage24:10 – How operating partners can support portfolio companies24:37 – The operating partner's role in due diligence25:35 – Identifying businesses that need growth intervention26:31 – Sharing best practices and coaching leadership teams26:59 – Sequencing growth initiatives effectively27:29 – How to connect with Brian Gustason27:57 – Closing remarksRaw Selection partners with Private Equity firms and their portfolio companies to secure exceptional executive talent. We focus on de-risking executive recruitment through meticulous search and selection processes, ensuring top-tier performance and long-term success.

I met Yonatan Sompolinsky in Romania during his summer holiday, so we decided to do a roadtrip interview about covenants, the state of Kaspa development, why intents are more interesting than smart contracts & stag hunts. 00:00:54 – Intro: a road trip with Yonatan Sompolinsky 00:01:50 – Life since S16 E41: Oxford Union & the state of Kaspa 00:02:53 – Kaspa shipped covenants while Bitcoin debates OP_CAT 00:04:24 – Sequencing commitments & based apps explained 00:06:48 – Why OP_CAT alone can't do censorship-resistant based rollups 00:07:21 – BitVM & optimistic vs optimistically verified rollups 00:08:05 – ZK was born for privacy but lives for scaling 00:09:18 – "For the record, I'm very bearish on rollups" 00:12:27 – Ethereum quietly abandons the L2 roadmap 00:13:33 – What ZK is actually for: a thin L1 & separation of layers 00:15:05 – Kaspa follows Bitcoin's UTXO design principles 00:16:04 – Ephemeral logic: generalized atomic swaps 00:17:25 – Camera gymnastics & an Aston Martin 00:19:28 – What covenants won't give you: the DeFi Lego box 00:20:05 – One-time logic vs contract deployment 00:23:18 – The use case question & crypto's crisis of utility 00:26:17 – Bitcoin the turtle & the DAGKnight progress report 00:28:17 – DAGKnight: 49% Byzantine resilience, no latency parameter 00:29:50 – Why 100 BPS on GHOSTDAG would 8x confirmation times 00:30:21 – Sponsors: Cake Wallet, LayerTwo Labs, Braiins, Orange Rock & SideShift 00:34:33 – Zcash made a comeback 00:35:19 – The mental map: where Kaspa is unique 00:38:49 – Real-time decentralization: sampling the honest majority 00:39:47 – Solana & Hyperliquid: fast, but led by one 00:42:46 – Only proof of work bundles proposing & content 00:44:35 – A bear market in usage, not just price 00:45:53 – Old-world use case: bridges & oracles 00:47:22 – Tourism break: Bușteni, mascots & ski resorts 00:49:38 – Hit-and-run agents & the agentic economy 00:51:06 – Having your cake and eating it too 00:54:32 – Vlad on Ecash, miner fees & Satoshi's biggest bet 00:56:37 – Sinaia & the royal train station 00:57:38 – "Bitcoin is dead boring to me at this stage" 00:59:50 – Ironwood, verifiable supply & Tachyon 01:00:39 – Driving like six confirmations 01:01:59 – The tectonic shift nobody noticed: verifying the supply 01:03:43 – The bug & Zcash's unfixable history 01:06:04 – Kaspa's pruning vs historical correctness 01:08:12 – How Zcash's rise paves the way for Kaspa 01:09:17 – The Zooko sleeping-in-the-car story 01:10:32 – "Just launch": Zooko one day before the Sapling bug 01:12:05 – Downplaying the bug & the counterfeit scenario 01:14:34 – Peter Todd's demurrage & the Ironwood migration 01:17:25 – Would any other coin survive this? 01:18:55 – Ethereum's identity crisis 01:21:28 – Back to L1: too little, too late; Solana's cohesion 01:22:46 – Oxford Union & political ambitions 01:24:44 – Hayek: true vs false individualism 01:26:04 – The isolated individual: Lopp, Poelstra & early Bitcoiners 01:32:52 – The enthusiastic individualist 01:34:52 – Coordination markets & Project Stag Hunt 01:35:19 – Prisoner's dilemma vs stag hunt 01:36:24 – Moloch, the demon of defection 01:37:18 – Part 2: stag hunt as the optimistic game 01:42:43 – Intents & NEAR Intents 01:44:03 – Intents vs smart contracts 01:45:21 – Part 3: Rousseau's ape men 01:49:45 – Intendos: "if many sign this, consider mine signed" 01:51:44 – Example: migrating a liquidity pool together 01:53:34 – Pack formation & threshold homomorphic encryption 01:55:42 – Actionable but not committed 01:57:18 – The Netflix example: voice for the scattered majority 02:01:36 – Who are the stags we need to hunt? 02:02:11 – Minarchist, anarchist or libertarian? 02:03:32 – Stag = shared utility; escaping Ethereum's L2 mess 02:06:28 – Composable Intendos 02:07:58 – Exiting network effects 02:09:11 – The Kaspa-Ethereum overlap: GHOST & Casper 02:11:55 – "I don't like DAGs": it's just a data structure 02:12:51 – Why DAGKnight survives a world war 02:15:22 – Michael Sutton & the Argent language 02:16:58 – Bypassing the impossibility theorem 02:18:06 – Ahead of his time or poor communicator? 02:19:31 – BPS vs TPS: the shift already happened 02:21:05 – Falling between the cracks 02:23:17 – The next narrative: coordination markets 02:24:26 – Brașov to Bucharest: documenting the trip 02:25:31 – Roles reversed: Yonatan interviews Vlad 02:27:06 – ACTA protests, internet freedom & political science 02:28:53 – Sztorc's party metaphor 02:29:57 – Zcash at $30 & the Coldcard hack 02:31:40 – What Kaspa actually needs: wallets, not exchanges 02:33:56 – Broadening cypherpunk: from protective to positive 02:37:16 – What have we really accomplished? 02:39:33 – Arriving at the Palace of Parliament 02:43:57 – The secret handshake & farewell

In this week's episode Brian and Jeff discuss why Social Security timing is really a tax sequencing decision and the Ripple Effect - how one tax decision can raise your Medicare premiums. 

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications

Welcome back to the Jack Westin MCAT Podcast with Mike and Molly! Last episode we covered DNA and RNA structure. Now we put that knowledge to work and answer the question that follows naturally: how do scientists actually study DNA, and how does the MCAT test those techniques?This is the DNA techniques episode, and it connects back to nearly everything you have already learned including amino acids, protein structure, hemoglobin, gel electrophoresis, blotting and central dogma.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HMB865. CME/EBAH/NCPD/CPE/AAPA credit will be available until July 24, 2027.Mapping the Pathways to Long-Term Treatment Benefit in Chronic Lymphocytic Leukemia (CLL): Strategies for Aligning Patient Priorities With Evidence for Initiating & Sequencing Targeted Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In today's episode, we spoke with Marlana M. Orloff, MD. Dr Orloff is the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. In our exclusive interview, Dr Orloff discussed the distinct biology of uveal melanoma and why it has historically resisted systemic treatment. Unlike cutaneous melanoma, which carries a high tumor mutational burden and responds robustly to immune checkpoint inhibitors, uveal melanoma sits at the opposite end of the spectrum with low mutational burden, a predominantly liver-metastatic pattern, and an immune-tolerant microenvironment that renders traditional immunotherapy largely ineffective.She provided context on the treatment landscape for patients with HLA-A*02:01–negative metastatic uveal melanoma prior to the phase 2/3 OptimUM-02 trial (NCT05987332), noting that this population had limited options: liver-directed therapies such as percutaneous hepatic perfusion, off-label immune checkpoint inhibitor combinations, or clinical trial enrollment.Dr Orloff then walked through the design and efficacy findings of the trial, which evaluated the combination of darovasertib, an oral PKC inhibitor, plus crizotinib (Xalkori), a MET inhibitor, vs investigator's choice in treatment-naive, HLA-A*02:01–negative patients. The combination demonstrated a median progression-free survival of 6.9 months vs 3.1 months with investigator's choice, with an objective response rate of 37.1% compared with under 5.8% in the control arm. She highlighted the clinical significance of the complete responses observed while noting that overall survival data from the phase 3 portion of the trial remain pending.The discussion also addressed the growing complexity of treatment sequencing as more options emerge, including tebentafusp-tebn (Kimmtrak) for HLA-A*02:01–positive patients, liver-directed and combination approaches, and the investigational TCR-engineered T-cell therapy anzutresgene autoleucel targeting PRAME. Dr Orloff emphasized that in the absence of head-to-head comparisons, sequencing decisions will increasingly be shaped by patient logistics, toxicity profiles, and access to specialized treatment centers.

Chris Ballew is BACK for his fifth Power Chord Hour appearance to talk about his 11th solo album Newborn Human, the making of the Presidents 1996 sophomore album II, if it's harder to open or close and album and lots more CHRIS BALLEW https://chrisballew.org https://chrisballew.bandcamp.com https://www.instagram.com/chrisballew https://www.instagram.com/pusaband PCH Instagram - www.instagram.com/powerchordhour Facebook - www.facebook.com/powerchordhour Youtube - www.youtube.com/channel/UC6jTfzjB3-mzmWM-51c8Lgg powerchordhour@gmail.com Donate to help show costs - https://www.paypal.com/paypalme/pchanthony https://cash.app/$anthmerch Check out the Power Chord Hour radio show every Friday night at 8 pm est/Tuesday at Midnight est on 107.9 WRFA in Jamestown, NY. Stream the station online at wrfalp.com/streaming/ or listen on the WRFA app/Apple CarPlay/Android Auto

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUQ865. CME/MOC/EBAH/NCPD/CPE/AAPA credit will be available until July 9, 2026.Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Chronic Lymphocytic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In today's episode, we spoke with Neil D. Gross, MD, FACS. Dr Gross is the medical director of Perioperative Surgical Services, section chief of Oropharynx Cancer, Surgery, and professor of head and neck surgery at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Gross discussed the key biological and clinical distinctions between cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), noting that although BCC is more indolent and less responsive to systemic therapies, including immunotherapy, CSCC carries a meaningful risk of nodal and distant metastases and has demonstrated robust responses to anti–PD-1 therapy, with approximately half of patients achieving a significant response.He emphasized the importance of early multidisciplinary evaluation, with resectability serving as a critical first branch point in treatment planning. For patients with unresectable or metastatic CSCC, anti–PD-1 therapy is now the established standard of care. For borderline resectable patients, such as those at risk for significant functional loss from surgery, upfront systemic therapy offers the potential to preserve function and achieve cure. For resectable, high-risk patients, Gross highlighted the role of adjuvant cemiplimab-rwlc (Libtayo) following surgery and radiation, based on data from the phase 3 C-POST trial (NCT03969004).The discussion also addressed toxicity considerations in elderly and immunocompromised patients, populations Gross described as particularly high risk and underserved. He noted that although anti–PD-1 therapies are generally well tolerated, serious toxicities remain possible, underscoring the importance of careful patient monitoring in both adjuvant and investigational neoadjuvant settings.Finally, Gross highlighted the actively accruing phase 3 NRG-HN014 trial (NCT06568172), a National Cancer Institute–sponsored cooperative group study open across the United States, Canada, and Australia, which is evaluating a neoadjuvant approach vs upfront surgery in patients with advanced resectable CSCC. He also noted that more mature data from C-POST, as well as long-term phase 2 neoadjuvant findings, are anticipated later this year. [CS1]https://faculty.mdanderson.org/profiles/neil_gross.html

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Dr. Pedro Barata and Dr. Giuseppe Curigliano discuss the rapid paradigm shift of antibody-drug conjugates into frontline advanced and curative-intent perioperative settings and the clinical challenges of optimal sequencing, target selection, and cross-resistance. LINK TO FULL TRANSCRIPT

In this episode, Dr. Marc Pietropaoli discusses his transition from traditional orthopedics to regenerative medicine, emphasizing the importance of repairing rather than replacing damaged joints. He shares insights on the components and sequencing of regenerative treatments, the role of genetic testing in nutrition, and his mission to eliminate the need for knee replacements by 2043. The conversation highlights the significance of prevention and proactive care in joint health. In this conversation, Dr. Marc Pietropaoli discusses various aspects of injury prevention, particularly focusing on ACL injuries and innovative surgical techniques. He emphasizes the importance of proper landing techniques, dynamic warm-ups, and the role of proprioception in preventing injuries. The discussion also covers the advancements in ACL repair, including the bear procedure, which utilizes a collagen implant to enhance healing and reduce the risk of arthritis. The conversation concludes with resources for further learning and insights into the future of sports medicine.   For Audience Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!      Takeaways        Dr. Pietropaoli transitioned from traditional orthopedics to regenerative medicine.        He emphasizes the body's ability to heal itself through regenerative techniques.        The importance of asking questions in medical training is highlighted.        Dr. Pietropaoli's personal experiences influenced his career path.        He advocates for a team approach in patient care, involving various specialists.        Inflammation is a key factor in joint health and must be addressed.        Genetic testing can guide nutritional choices for better health outcomes.        Preventive measures can significantly reduce the risk of joint injuries.        Dr. Pietropaoli aims to end the need for knee replacements by 2043.       The conversation underscores the importance of patient education in exploring treatment options. Bending knees during landing reduces injury risk.        Proper proprioception is crucial for athletes.        Dynamic warm-ups are more effective than static stretching.        Mastering two-legged exercises is essential before progressing to one-legged ones.        Plyometrics enhance fast twitch muscle fiber development.        Agility is linked to balance and quickness.        Bear surgery offers a promising alternative to traditional ACL repair.        Collagen implants can significantly aid in ACL healing.        Using blood flow restriction can enhance recovery post-surgery.        Education and awareness are key in sports injury prevention.     Chapters 00:00 Introduction to Regenerative Orthopedics 04:08 The Journey from Traditional to Regenerative Medicine 13:46 Components and Sequencing in Regenerative Treatments 20:04 Genetic Testing and Nutrition for Optimal Health 22:52 Future Aspirations in Joint Health and Prevention 27:09 Injury Prevention Techniques 34:06 Understanding ACL Injuries and Repair 42:35 Innovations in ACL Surgery 45:34 Resources and Final Thoughts   To learn more about Dr. Marc: Website: www.victoryinmotion.com TikTok: https://www.tiktok.com/@drmarcpietropaoli Instagram: https://www.instagram.com/drmarcpietropaoli LinkedIn: https://www.linkedin.com/in/drmarcpietropaoli YouTube: https://www.youtube.com/@victoryinmotion1   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw     Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.  

In this special episode, we revisit a fireside conversation between Vitalik Buterin and Friederike Ernst at DappCon 2026 in Berlin. They explore the Ethereum Economic Zone (EEZ), a new vision for Ethereum built around synchronous composability, app chains, and real-time proving.Following the fireside, Sebastien and Friederike break down the ideas behind the EEZ and discuss what this new paradigm could mean for Ethereum's future.Topics covered include:• The Ethereum Economic Zone and synchronous composability• App chains, privacy networks, and prediction markets• Ethereum as an economic operating system for the internet• Sequencing, MEV, and shared liquidity across chains• Enterprise, government, and institutional use cases• Why this approach differs from Cosmos, Polkadot, and other ecosystem visions• The future of Ethereum beyond rollup fragmentationLinks:Lido: https://lido.fi/stvaults?mtm_campaign=epicenterSponsors: Lido V3 introduces stVaults: a modular staking infrastructure that lets builders and institutions deploy custom staking vaults, while staying anchored to stETH as a shared liquidity layer.Get started building with Lido V3 today: https://lido.fi/stvaults?mtm_campaign=epicenterBlock Space Forum: https://blockspace.forum/NEAR AI Cloud now lets developers deploy OpenClaw—the rapidly growing open-source AI agent platform—inside Trusted Execution Environments, providing hardware-level encryption with cryptographic attestations. With OpenClaw on NEAR AI Cloud, you can run agents with cloud convenience, but without traditional cloud data exposure. No hardware to manage. No trust assumptions required. Learn more at near.ai.

Sequencing departures like a moving puzzle, scrambling when a jet takes off without clearance, and catching what radar misses with a glance out the window with Michael Rejent, an air traffic controller. What does "tally ho" mean to a pilot? What phrase makes every controller in the cab look up?WANT MORE EPISODE SUGGESTIONS? Grab our What It's Like To Be... "starter pack". It's a curated Spotify playlist with some essential episodes from our back catalogue.GOT A COMMENT OR SUGGESTION? Email us at jobs@whatitslike.comFOR SPONSORSHIP OPPORTUNITIES: Email us at partnerships@whatitslike.comWANT TO BE ON THE SHOW? Leave us a voicemail at (919) 213-0456. We'll ask you to answer two questions:1. What's a word or phrase that only someone from your profession would be likely to know and what does it mean?2. What's a specific story you tell your friends that happened on the job? It could be funny, sad, anxiety-making, pride-inducing or otherwise.We can't respond to every message, but we do listen to all of them! We'll follow up if it's a good fit.

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

What does it take to go from working at the bench to becoming a future clinical microbiology laboratory director? In this episode, Luis is joined by Dr. Mackenzie Collins, a CPEP fellow at UCLA, to discuss her journey from Medical Laboratory Scientist (MLS) to PhD scientist and CPEP fellow. Mackenzie shares how she discovered laboratory medicine, her experience working as an MLS in molecular microbiology, and the mentors and opportunities that helped shape her career path. The conversation explores the CPEP fellowship, the role of laboratory directors, and how MLS professionals can strengthen their applications through projects, research, presentations, and professional involvement. Mackenzie also discusses her PhD work involving HIV reservoirs and long-read sequencing, and why genomics and molecular diagnostics will continue to play an increasingly important role in clinical microbiology. Whether you're considering graduate school, interested in the CPEP fellowship, or exploring career paths in laboratory medicine, this episode offers a firsthand look at one MLS's journey from the bench to clinical microbiology leadership. Topics discussed: The MLS-to-CPEP pathway and transitioning from the bench to graduate school Mentorship, professional development, and building a competitive application The role of clinical microbiology laboratory directors and career opportunities beyond the bench Sequencing, genomics, and the future of clinical microbiology Additional Resources CPEP Fellowship Overview with Dr. Sam Goodfellow Interested in learning more about the CPEP Fellowship? In this episode, Dr. Sam Goodfellow discusses the structure of the program, the application process, and what to expect from CPEP training. https://directory.libsyn.com/episode/index/id/36395120 Understanding the ABMM Certification Examination Learn more about the American Board of Medical Microbiology (ABMM) certification, its importance for future laboratory directors, and what candidates can expect from the examination process. https://directory.libsyn.com/episode/index/id/35868345 Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8 Support the podcast: Venmo Buy me a Ko-fi  

What if one proven methodology could turn B2B market share from stagnant to soaring, with a track record of guaranteed growth, yet almost no U.S. company has heard of it? In this episode of Predictable B2B Success, we speak with Hugo Van Den Biggelaar, a former Nike brand strategist turned evangelist for Bitsing, a 33-year-old European methodology that has fueled BMW, Shell, HP Enterprise, and thousands of organizations, with no failures on record. Hugo, now based in Brooklyn, New York, challenges core assumptions about B2B growth. He says most companies aren't failing because they do the wrong things, but because they do the right things in the wrong order and at the wrong time. What is the hidden sequence behind sustained revenue, and why is “brand awareness” sometimes a death trap? Hugo reveals why even the most successful B2B teams often aim at the wrong goals, how to build a “golden egg” competitors can't copy, and why emotional preference, not rational decision-making, drives billion-dollar deals. Why your growth efforts stall or how sales, marketing, and product can actually align, this conversation will leave you rethinking everything you know about predictable B2B success. Some topics we explore in this episode include: The Bitsing Methodology: Origins, proven track record, and impact on companies worldwideRight Actions, Wrong Sequence: How companies undermine growth by doing the right things in the wrong orderFinancial Goal Setting: The necessity of clear financial (not just KPI) goals: continuity, ambition, and dreamOrganizational Alignment: The need for unified goals and eliminating departmental silosThe Seven Principles/Steps: The stepwise framework that drives predictable growthData-Driven Focus: The Pencil Method: Using facts (not gut) to determine where revenue actually comes fromThe Golden Egg: Emotional Differentiation: Creating an emotional, uncopyable reason for customers to choose your brandStrategies vs. Goals: The common mistake of confusing means with ends 17:12.Driving Preference and Loyalty: Preference as the key to growth and how to create genuine, unconditional loyaltyPlan Execution & Guaranteed Results: The phases of implementation and what “guaranteed growth” means with Bitsing

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Trump's Raúl Castro move and what it signals for Cuba. Patrick Bet-David and the panel explain why the 1996 Brothers to the Rescue shootdown indictment matters now, call out Obama's friendly Cuba photo ops, and debate whether Trump is quietly setting up post-Castro regime change.

Today, we are breaking down Auto1, and this is an interesting episode because we are tackling a business that most US listeners will not be familiar with, even though it resembles names they already know well. Our guest is Harrison Moot, co-founder and CIO of Sandstone, who walks us through Europe's largest vertically integrated online marketplace for used cars. Auto1 is often shorthanded as the Carvana of Europe, and the comparison directionally fits, but the differences are what make the company worth understanding on its own terms. The core of the conversation is how Harrison frames the company. He argues that Auto1 is best understood as a pan-European clearing house for used vehicles rather than a dealer with a website, and that the model only works because the company built its consumer sourcing engine and its wholesale dealer liquidity for nearly a decade before ever launching the consumer retail business. Owning the sourcing, logistics, refurbishment, and financing stack across thirty fragmented national markets gives Auto1 a pricing and routing advantage that local dealers and asset-light classifieds cannot replicate. Please enjoy this Breakdown of Auto1. For the full show notes, transcript, and links to the best content to learn more, check out the episode page⁠⁠⁠⁠⁠⁠⁠ here.⁠⁠⁠⁠⁠⁠⁠ ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at ⁠colossus.com/subscribe⁠. ----- This episode is brought to you by⁠⁠⁠⁠ ⁠Portrait Analytics⁠⁠⁠⁠⁠ - your centralized resource for AI-powered idea generation, thesis monitoring, and personalized report building. Built by buy-side investors, for investment professionals. We work in the background, helping surface stock ideas and thesis signposts to help you monetize every insight. In short, we help you understand the story behind the stock chart, and get to "go, or no-go" 10x faster than before. Sign-up for a free trial today at ⁠⁠⁠⁠⁠portraitresearch.com⁠⁠⁠⁠⁠ ----- Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Timestamps (00:00:00) Welcome to Business Breakdowns (00:03:35) Auto1 Business Overview  (00:07:06) European Market & C2B Model  (00:12:31) Founding Story & Sequencing  (00:16:39) Why Cazoo Failed  (00:16:42) Cazoo vs. Auto1 Approach  (00:18:29) How a Transaction Works  (00:22:11) Dealer Buying Patterns  (00:25:49) Retail vs. Wholesale  (00:26:18) Consumer Financing & ABS  (00:27:57) ABS Lowers Funding Costs  (00:28:16) Unit Economics by Segment  (00:32:37) Network Effects & Data Moat  (00:37:35) Path to Margin Expansion  (00:42:23) Balance Sheet & Working Capital  (00:44:40) Four Growth Levers  (00:48:27) Dealers: Customers Not Competitors  (00:53:17) Four Key Business Risks  (00:54:12) Inventory Risk & Mitigants  (00:58:32) Valuation Framework & Multiples  (01:03:14) Vertical Integration & Capital Cycles